Objective:

To explore the role of IL-6 as a therapeutic target and review current IL-6 inhibitor therapies for noninfectious uveitis (NIU), highlighting its significance in treatment.

Key Findings:

• Tocilizumab has shown efficacy in treating refractory NIU and associated cystoid macular edema, as demonstrated in the STOP-Uveitis trial.
• Clinical trials demonstrated significant improvement in best-corrected visual acuity (BCVA) and reduction in central macular thickness with tocilizumab, particularly in multicenter studies.
• Sarilumab also resulted in significant decreases in vitreous haze and improved BCVA compared to placebo, as shown in the SATURN study.

Interpretation:

IL-6 inhibitors represent a promising therapeutic option for patients with refractory NIU, potentially improving visual outcomes and reducing inflammation, though further research is essential.

Limitations:

• Limited long-term safety data for IL-6 inhibitors in uveitis, with variability in patient response and potential adverse effects such as infections.

Conclusion:

IL-6 inhibition is a viable treatment strategy for noninfectious uveitis, with ongoing research needed to further establish efficacy and safety, particularly regarding long-term outcomes.